Compare Core Scientific Inc (CORZ) vs 10X Genomics Inc (TXG) Price & Performance

Core Scientific (CORZ) trades at $15.41, down 3.32% today, with bearish technical signals and significant fundamental challenges. The company reported a net loss of $288.62 million in 2025 with negative profit margins, though revenue grew to $319.02 million. Analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.75 consensus price target, while recent news highlights the company's pivot toward AI data center operations and insider buying activity.

Despite strong analyst support, CORZ faces substantial execution risks in its AI infrastructure transition amid persistent losses and negative cash flow. The stock's current price near key support levels presents potential upside if the company can achieve profitability, but investors should weigh the high-risk profile against the optimistic Wall Street projections.

TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.

The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.